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Preservation of the metabolic rate of oxygen in preterm
infants during indomethacin therapy for closure of the ductus
arteriosus
Rohit Arora1, Mustafa Ridha2,3, David S. C. Lee1, Jonathan Elliott2,3, Herschel C. Rosenberg4, Mamadou Diop2,3, Ting-Yim Lee2,3,5
and Keith St. Lawrence2,3

Background: The aim of this study was to assess and quantify the effects of indomethacin on cerebral blood flow (CBF),
oxygen extraction fraction (OEF), and cerebral metabolic rate
of oxygen (CMRO2) in preterm infants undergoing treatment
for a patent ductus arteriosus (PDA).
Methods: CBF and CMRO2 were measured before and after
the first dose of a 3-d course of indomethacin to close hemodynamically significant PDA in preterm neonates. Indocyaninegreen (ICG) concentration curves were acquired before and
after indomethacin injection to quantify CBF and CMRO2.
Results: Eight preterm neonates (gestational age,
27.6 ± 0.5 wk; birth weight, 992 ± 109 g; 6 males:2 females) were
treated at a median age of 4.5 d (range, 4–21 d). Indomethacin
resulted in an average CBF decrease of 18% (pre- and postCBF = 12.9 ± 1.3 and 10.6 ± 0.8 ml/100 g/min, respectively)
and an OEF increase of 11% (pre- and post-OEF = 0.38 ± 0.02
and 0.42 ± 0.02, respectively) but no significant change in
CMRO2 (pre- and post-CMRO2 = 0.83 ± 0.07 and 0.76 ± 0.07 ml
O2/100 g/min, respectively). Corresponding mean blood pressure (BP), arterial oxygen saturation (SaO2), heart rate, and endtidal carbon dioxide tension levels remained unchanged.
Conclusion: Indomethacin resulted in significant reduction in CBF but did not alter CMRO2 because of a compensatory increase in OEF.

T

he incidence of patent ductus arteriosus (PDA) is inversely
related to birth weight and gestational age; ~40% of infants
with PDA are below 1,000 g or of a gestational age <28 wk
(1,2). Preterm infants with PDA are at greater risk of pulmonary edema and hemorrhage, bronchopulmonary dysplasia,
and decreased perfusion and oxygen delivery to the organs,
including the brain (3). Reduced cerebral perfusion has been
implicated in the higher incidence of intraventricular hemorrhage and periventricular leucomalacia (4,5). Consequently,
management of preterm infants with clinically significant
PDA has focused on ductal closure by either nonsteroidal antiinflammatory drugs or, if necessary, surgical ligation.

Primary treatment is typically with a cyclooxygenase inhibitor, either indomethacin or ibuprofen (6,7). These drugs
inhibit the production of prostaglandins, causing a functional
constriction of the ductus arteriosus, which induces anatomical remodeling and ultimately ductal closure. Both drugs are
equally effective, with a success rate between 60 and 80% (8).
However, a well-known difference between indomethacin
and ibuprofen is the vasoconstricting effect of the former,
which has been shown to reduce renal and cerebral perfusion.
Cerebral blood flow (CBF) reductions ranging from 12 to 40%
have been reported using a variety of blood flow measurement techniques, including the 133Xenon clearance technique
(9), near-infrared spectroscopy (NIRS) (10,11), and Doppler
ultrasound (12,13). Considering that this is a patient population that is already at high risk of brain injury, alterations in
cerebral hemodynamics as a consequence of PDA treatment
remain a concern (7), particularly if these reductions are large
enough to affect cerebral energy metabolism.
NIRS studies have shown that indomethacin can alter cerebral oxygenation such as the fractional tissue oxygen extraction, although the magnitude of the changes appears to depend
on the infusion protocol (5,14,15). Interpreting cerebral oxygenation in terms of energy metabolism is difficult because
cerebral blood oxygenation depends on the balance between
oxygen delivery and consumption. Earlier studies investigating
the effects of indomethacin on cerebral cytochrome oxidase
reported reduction in the oxidized state (16–18). However, no
study has directly measured the effects of indomethacin on the
cerebral metabolic rate of oxygen (CMRO2), despite the ability
of NIRS to determine CMRO2 by combining cerebral flow and
oxygenation measurements (19–21).
The purpose of the current study was to measure CBF, oxygen
extraction fraction (OEF), and CMRO2 in preterm infants who
were undergoing treatment with indomethacin for a hemodynamically significant PDA. Measurements were obtained
before and immediately following the infusion of the first dose
of the drug, which was part of a standard three-dose (one dose
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per day) protocol. CBF was measured with a bolus-tracking
NIRS technique using the light-absorbing dye indocyanine
green (ICG) as an intravascular contrast agent (22). This dye
has been used previously to measure CBF in preterm infants
and has a good safety record: the incidence of systemic allergic reactions is ~1:250,000 (23,24). CMRO2 was determined by
combining NIRS measurements of CBF and the cerebral concentration of deoxyhemoglobin [HHb] (25).
RESULTS
Complete data sets (i.e., both NIRS and the dye densitometer data before and after first treatment dose) were obtained
from 8 of 10 infants. Data from the remaining two sets were
excluded because of poor-quality arterial ICG concentration
curves as a result of motion artifacts. Baseline clinical details
from the remaining infants are given in Table 1. The studied
cohort had a gestational age (mean ± SE) of 27.6 ± 0.5 wk and
a birth weight of 992 ± 109 g. The median age of treatment was
4.5 d (range; 4–21 d).
Figure 1 illustrates arterial and tissue ICG concentration
curves, pre- and post-treatment, from one infant. These curves
show the typical first pass of ICG in blood and brain due to the
rapid bolus injection of the dye. The magnitude of the first pass
is diminished after indomethacin infusion (Figure 1b), reflecting the reduction in CBF. In this example, CBF decreased
from 17.7 to 11.8 ml/100 g/min after indomethacin treatment.
Figure 2 shows the individual pre- and post-treatment values
of CBF, cerebral blood volume (CBV), OEF, and CMRO2. A
general reduction in CBF and CBV was observed as expected
due to the known vasoconstricting effects of indomethacin.
A concurrent increase in OEF was found, whereas CMRO2
displayed no significant change. These observations were confirmed by the mean pre- and post-treatment values given in
Table 2. Indomethacin caused a significant decrease in CBF

of 18% (P < 0.025) and in CBV of 15% (P < 0.02). There was
a significant increase in OEF of 11% (P < 0.025), but the drug
had no overall effect on CMRO2.
Included in Table 2 are the mean values of arterial oxygen
saturation (SaO2), heart rate, mean blood pressure (BP), and
transcutaneous carbon dioxide before and after treatment;
none of them were found to change significantly after the drug
infusion. The PDA was closed in all eight cases after the threedose regimen of indomethacin. Five ducts remained closed
whereas three reopened at a later time and received further
indomethacin courses. One of the three cases responded to the
second course of indomethacin, whereas the remaining two
underwent surgical ligation.
DISCUSSION
The principal finding of this study was that, despite the significant reductions in CBF and CBV caused by a 30-min infusion
of indomethacin, there was no change in CMRO2. This finding
was not unexpected, considering that under normal conditions, CMRO2 should remain stable during relatively moderate
reductions in CBF due to a compensatory increase in OEF. In
this study, the 18% reduction in CBF was accompanied by a
statistically significant increase in OEF of 11%. These results
suggest that, even at this very early age, the cerebral oxygen
a
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Table 1. Baseline clinical parameters
Value

Gestational age (weeks)

27.6 ± 0.5

Birth weight (g)

992 ± 109

Gender (M/F)

6:2

Apgar score at 1 min (median (range))

3 (1–8)

Apgar score at 5 min (median (range))

6 (2–9)

Mechanically ventilated (%)
IMV

75

CPAP

25

HFV

0

Total hemoglobin (g/dl)

13.3 ± 0.6

IVH grade (%)
1

25

2

0

Values are mean ± SE unless otherwise noted (n = 8).
CPAP, continuous positive airway pressure; F, female; HFV, high-frequency ventilation;
IMV, intermittent mandatory ventilation; IVH, intraventricular hemorrhage; M, male.
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Figure 1. Arterial (solid line) and brain (dashed line) ICG concentration
curves measured by dye densitometry and near-infrared spectroscopy,
respectively. Data shown are from one infant (a) before and (b) after first
treatment dose of indomethacin. Each set of arterial and tissue curves was
measured simultaneously after injecting a solution of ICG (0.1 mg/kg at a
concentration of 0.5 mg/ml). For visualization, the tissue curves have been
scaled by a factor of 20 because the cerebral blood volume is ~5% of the
total tissue volume. ICG, indocyanine green.
Copyright © 2013 International Pediatric Research Foundation, Inc.
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Figure 2. Individual values of pre- and post–single indomethacin treatment of patent ductus arteriosus for (a) cerebral blood flow (CBF), (b) cerebral
blood volume (CBV), (c) oxygen extraction fraction (OEF), and (d) the cerebral metabolic rate of oxygen (CMRO2) (n = 8, indomethacin dose = 0.2 mg/kg).
Data from each patient are represented by the same symbol and type of line in all graphs.

supply is sufficient to accommodate moderate variations in
cerebral perfusion. Nevertheless, an increase in OEF does
indicate that the cerebrovascular oxygen reserve is diminished
by indomethacin, and any further reduction in either CBF or
arterial oxygen tension during this period of vasoconstriction
could potentially affect CMRO2.
The vasoconstricting effects of indomethacin are well known
and are probably brought about by an action independent of
its effect on prostaglandins because ibuprofen does not have
the same effect on CBF (10). Other actions of indomethacin
include inhibition of histamine release (26) and an enhancement of the lipoxygenase pathway (27). In addition, the effects
of indomethacin on CBF appear to be dependent on the infusion rate. The 30-min infusion protocol used in the current
study was based on a recent Cochrane review that recommended this duration to reduce perfusion effects without any
loss of efficacy (28). The 18% reduction in CBF would appear
to be in good agreement with the range of perfusion changes
reported in previous studies using different infusion protocols.
For the same dose, Patel et al. reported a greater CBF reduction (~40%) when indomethacin was infused over 15 min (10).
Significant reductions in CBF velocities measured by Doppler
ultrasound have also been reported for infusion durations of

Table 2. Clinical parameters and near-infrared spectroscopy
measurements before and after indomethacin infusion
Parameter

Pre-treatment

Post-treatment

BP (mm Hg)

36.9 ± 2.7

38.7 ± 2.8

EtCO2 (mm Hg)

56.1 ± 2.4

56.0 ± 2.2

pH

7.28 ± 0.02

7.25 ± 0.01

Heart rate (beats/min)

152 ± 4

156 ± 3

SaO2 (%)

93.6 ± 1.9

93.0 ± 2.0

CBF (ml/100 g/min)

12.9 ± 1.3

10.6 ± 0.9*

CBV (ml/100 g)

2.14 ± 0.15

1.73 ± 0.10*

OEF

0.38 ± 0.02

0.42 ± 0.02*

CMRO2 (ml O2/100 g/min)

0.83 ± 0.07

0.76 ± 0.07

Values are mean ±SE (n = 8).
BP, blood pressure; CBF, cerebral blood flow; CBV, cerebral blood volume; CMRO2,
cerebral metabolic rate of oxygen; EtCO2, end-tidal carbon dioxide tension; OEF, oxygen
extraction fraction; SaO2, oxygen saturation.
*Significant change with treatment (P < 0.05).

the order of 30 min or less (12,29). For durations greater than
2 h, no significant change in CBF velocity was found (29,30).
Similarly, Lemmers et al. reported no change in cerebral blood
oxygenation with a 60-min infusion protocol (5).
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In contrast to its effects on cerebral hemodynamics, the
potential metabolic effects of indomethacin are less clear.
Earlier NIRS studies reported significant reductions in the
concentration of oxidized cytochrome oxidase after indomethacin infusion (16–18). The study by McCormick et al.
used a 30-min infusion protocol similar to the one in the current study (17). However, it was concluded that the observed
effects were more likely a result of a reduction in oxygen
delivery (i.e., CBF), rather than a direct effect on mitochondrial respiration because the concentration of oxidized cytochrome oxidase depends on the balance between oxygen
delivery and utilization. Indirect evidence that indomethacin does not alter cerebral metabolism is found in the recent
study showing no effects of the drug on electroencephalogram recording (31). Decreased CMRO2 has been reported in
animal studies; however, these changes were found either at
a high dose (5 mg/kg) or during hypotension (32,33). Using
the same infusion protocol and the same NIRS techniques,
our group previously reported, in newborn piglets, that indomethacin significantly reduced CBF but had no effect on
CMRO2 (34). These results substantiate the main finding of
the current clinical study.
To the best of our knowledge, this study is the first in
infants to report quantitative measurements of CBF and
CMRO2 obtained using ICG as a contrast agent. The idea
of using ICG for this purpose was initially proposed by
Patel et al. to improve the precision of CBF measurements
as compared with those obtained using the hemoglobin
wash-in technique (23). However, their approach required
the use of an arterial catheter to measure the arterial ICG
concentration curve, Ca(t). Our group has improved on this
methodology by using dye densitometry to measure Ca(t)
noninvasively and incorporating a deconvolution routine
in the data analysis to further improve the precision of the
CBF measurements. Repeated measures demonstrated that
CBF could be measured with a precision of better than 10%
(22). The CBF and CMRO2 measurements obtained with this
technique have been validated in multiple animal-model
studies (22,25).
In preterm infants, global CBF is expected to be in the order
of 15 ml/100 g/min, which is in good agreement with the mean
value reported in the current study (12.9 ± 1.3 ml/100 g/min)
(35). Values in this range have been previously reported
using a variety of perfusion techniques, including 133Xenon
clearance and various NIRS methods (10,20,35). An average CMRO2 of 0.83 ± 0.06 ml O2/100 g/min was also in good
agreement with previous NIRS studies (19–21). Using the partial venous occlusion method, Yoxall and Weindling reported
a median CMRO2 of 0.47 ml O2/100 g/min for a group of 20
neonates with a median gestational age of 27 wk (21). Elwell
et al. reported a median CMRO2 of 1.03 ml O2/100 g/min in
a cohort of nine preterm infants with a median gestation age
of 25 wk (19). The approach used by Elwell et al. was similar
to that of the current study given that estimates of cerebral
venous saturation were obtained assuming a venous fraction
of 0.75.
716 Pediatric Research      Volume 73 | Number 6 | June 2013

One limitation of this study was the occurrence of motion
artifacts during the 60-s recording period, which was primarily
a challenge for measuring the arterial ICG concentration curve
by dye densitometry. To minimize motion, the acquisition of
the ICG data was often delayed 5–10 min after placing the NIRS
and dye densitometer probes on the head and hand, respectively.
However, it is very difficult to control for all motions and, in this
small cohort of 10 patients, it was necessary to omit two data sets.
This failure rate is similar to that of the study by Leung et al., in
which 7 of 25 trials (28%) were excluded using dye densitometry
to measure CBV (36). Another limitation of the current study
was that the number of CBF measurements was restricted to two
because of safety concerns with injecting an exogenous contrast
agent. This prevented monitoring CBF during indomethacin
infusion to determine if CBF potentially falls to lower values,
or monitoring for longer period after the injection to determine
when CBF returned to preinfusion levels. One solution would
be to combine the ICG bolus-tracking method with diffuse correlation spectroscopy to provide continuous monitoring of CBF
without the need for repeat ICG injections (37).
In this study, we used a previously validated NIRS method
to investigate the effects of indomethacin on CBF and CMRO2
in preterm infants with clinically significant PDA. The results
confirmed the expected decrease in CBF following indomethacin infusion; however, CMRO2 remained at preinfusion levels due to a significant increase in the OEF. These findings of
decreased CBF with preserved CMRO2 may help explain why
indomethacin prophylaxis decreases the incidence of severe
intraventricular hemorrhage, being that CMRO2 probably
remains stable during large arterial BP fluctuations (38). The
baseline CBF and CMRO2 values were also in good agreement
with previous studies. These results suggest that this methodology could be used for bedside assessments with other clinical
conditions that have the potential to affect cerebral hemodynamics and energy metabolism.
METHODS

Patient Population
Preterm infants (gestational age <30 wk) with hemodynamically significant PDA were enrolled in the study after obtaining informed and
written parental consent. The diagnosis of PDA was based on clinical
indexes (systolic murmur, wide pulse pressure, increased respiratory
support, and metabolic acidosis) and confirmed by echocardiography
(left atrium/aorta ratio >1.4, internal ductal diameter >2 mm, and/or
left pulmonary artery end diastolic flow velocity >0.2 m/s). Infants
were excluded if diagnosed with severe intraventricular hemorrhage
(grade III or IV, Papile classification), major congenital malformations, or persistent hypotension requiring inotropic support. The
study was approved by the Health Sciences Research Ethics Board of
Western University, London, Ontario, Canada.
NIRS
All NIRS data were collected with a continuous-wave, broadband (600–
980 nm) system using two fiber-optic bundles, one for light emission
and the other for detection (22). The ends of the fiber bundles were
held 3.5 cm apart using a custom-built holder that was strapped to
the infant’s head to position the probes over the frontoparietal region.
The concentrations of ICG and [HHb] were determined by secondderivative spectroscopy (39). With this approach, light attenuation is
converted into chromophore concentration assuming water content in
brain of 85%.
Copyright © 2013 International Pediatric Research Foundation, Inc.
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The NIRS technique for measuring CBF required an intravenous
bolus
injection of ICG (22). The time-dependent concentration of

ICG in brain, Q(t), is related to CBF by the following equation:
t

Q(t ) = CBF ∫ Ca (u) ⋅ R(t − u) du

(1)

0

where Q(t) was determined from the NIRS absorption measurements
acquired at a temporal resolution of 200 ms. The time-dependent
concentration of ICG in arterial blood, Ca(t), was measured noninvasively by a dye densitometer (DDG-2001 A/K, Nihon Kohden, Tokyo,
Japan) attached to a foot. The remaining function, R(t), is the impulse
residue function; it represents the amount of ICG in brain tissue following an idealized bolus injection of unit concentration (40). The
product CBF·R(t) was extracted from the measured Q(t) and Ca(t)
data by deconvolution (22). The initial height corresponds to CBF
because by definition, R(t) has an initial value of 1, and CBV was
determined from the area under CBF·R(t).
The method used to calculate CMRO2 was based on the Fick
principle:


CMRO2 = CBF ⋅ AVDO2

(2)

where AVDO2 is the cerebral arteriovenous oxygen difference.
Because the second-derivative method does not provide a reliable
estimate of oxyhemoglobin (39), the venous concentration of oxygen,
[O
 2]v, was determined from the NIRS [HHb] measurement acquired
before injecting ICG (25):



1  [HHb]
[O2 ]v = 1.39 ⋅ [tHb] − 
− (1 − f v )[HHb]α   (3)
f v  CBV ⋅ ρ


where the factor 1.39 describes the amount of O2 (in ml) bound per
gram of hemoglobin; [tHb] is the total hemoglobin concentration; ρ is
the density of brain tissue (1.05 g/ml); [HHb]a is the arterial concentration of deoxyhemoglobin, which was determined from the arterial
SaO2; and fv is the assumed venous blood fraction (0.75). In this equation, the term CBV·ρ converts the NIRS tissue [HHb] measurement
to an equivalent blood measurement.
The fraction of oxygen extracted into brain, OEF, was calculated by

OEF =

[O2 ]a − [O2 ]v
[O2 ]a

(4)

Study Design
Pharmacological treatment of PDA followed the standard indomethacin dosage schedule consisting of three doses of 0.2 mg/kg, separated
by 24 h, infused intravenously over 30 min. Two NIRS data sets were
acquired on the first day of treatment, one ~5 min before the start of
drug infusion and the other immediately at the end of 30-min infusion. The acquisition period for each ICG run was ~80 s, with the
dye injected (0.1 mg/kg at a concentration of 0.5 mg/ml sterile water,
BCD Pharma, Mississauga, Ontario, Canada) around the 10 s mark
using a preexisting central-line catheter. The tissue and arterial ICG
concentration curves were acquired simultaneously by NIRS and the
dye densitometer, respectively. The fiber-optic probes remained in
the same position on the head throughout the treatment to eliminate
potential variations associated with probe re-positioning. Clinical
data, including SaO2, heart rate, BP, transcutaneous carbon dioxide,
capillary blood gases and [tHb], the mode of ventilation, and urine
output, were also recorded.
Statistical Analysis
SPSS 15.0 (SPSS, Chicago, IL) was used for all statistical analysis.
A paired t test was used to determine significant differences before
and after indomethacin infusion. The analysis was conducted for
CBF, OEF, and CMRO2, as well as for clinical parameters measured

Articles

pre- and post-treatment (SaO2, heart rate, BP, pH, and transcutaneous
carbon dioxide). Statistical significance for all tests was based on a P
value < 0.05. All data are presented as mean ± SE, unless otherwise
stated.
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